Patents by Inventor Wojciech Ardelt

Wojciech Ardelt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating infections originating from viruses in the herpesviridae family
    Patent number: 8808690
    Abstract: Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: August 19, 2014
    Assignee: Tamir Biotechnology, Inc.
    Inventors: Shailendra K. Saxena, Wojciech Ardelt
  • Methods of treating human papillomavirus
    Patent number: 8663964
    Abstract: Two RNases (ranpirnase and the second embodiment disclosed in U.S. Pat. No. 5,728,805) are tested against human papillomavirus infections. QRT-PCR assays indicate that the RNases have anti-viral activity against type 11 HPV.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: March 4, 2014
    Assignee: Tamir Biotechnology, Inc.
    Inventors: Shailendra K. Saxena, Wojciech Ardelt
  • METHODS OF TREATING INFECTIONS ORIGINATING FROM VIRUSES IN THE HERPESVIRIDAE FAMILY
    Publication number: 20140037610
    Abstract: Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.
    Type: Application
    Filed: July 26, 2013
    Publication date: February 6, 2014
    Applicant: Tamir Biotechnology, Inc.
    Inventors: Shailendra K. SAXENA, Wojciech ARDELT
  • METHODS OF TREATING KAPOSI'S SARCOMA
    Publication number: 20140030246
    Abstract: Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.
    Type: Application
    Filed: July 26, 2013
    Publication date: January 30, 2014
    Applicant: Tamir Biotechnology, Inc.
    Inventors: Shailendra K. SAXENA, Wojciech ARDELT
  • Methods of treating infections originating from viruses in the herpesviridae family
    Patent number: 8518399
    Abstract: Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: August 27, 2013
    Assignee: Tamir Biotechnology, Inc.
    Inventors: Shailendra K. Saxena, Wojciech Ardelt
  • METHODS OF TREATING HUMAN PAPILLOMAVIRUS
    Publication number: 20130022589
    Abstract: Two RNases (ranpirnase and the second embodiment disclosed in U.S. Pat. No. 5,728,805) are tested against human papillomavirus infections. QRT-PCR assays indicate that the RNases have anti-viral activity against type 11 HPV.
    Type: Application
    Filed: July 20, 2011
    Publication date: January 24, 2013
    Applicant: TAMIR BIOTECHNOLOGY, INC.
    Inventors: Shailendra K. Saxena, Wojciech Ardelt
  • METHODS OF TREATING INFECTIONS ORIGINATING FROM VIRUSES IN THE HERPESVIRIDAE FAMILY
    Publication number: 20120121569
    Abstract: Three RNases (ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2) are tested against identified herpesviridae infections. With some exceptions, quantitative PCR assays indicate that the RNases have anti-viral activity against many of these viruses.
    Type: Application
    Filed: November 17, 2010
    Publication date: May 17, 2012
    Applicant: Tamir Biotechnology, Inc.
    Inventors: Shailendra K. Saxena, Wojciech Ardelt
  • Mutant form of cytotoxic ribonucleolytic protein which allows production by recombinant methods
    Patent number: 6649393
    Abstract: The present invention provides recombinant Onc (rOnc) compositions and methods. Recombinant Onc proteins of the invention have an amino terminal methionine and comprise an Onc polypeptide. The amino terminal methionine of the protein allows for recombinant production in a bacterial host cell. Cleaving the amino terminal methionine exposes the amino terminal glutamine of the polypeptide. The Onc polypeptide has an amino terminal glutamine. Cyclization of the amino terminal glutamine of the polypeptide to a pyroglutamyl residue provides rOnc polypeptides and proteins have anti-cancer and anti-viral activity.
    Type: Grant
    Filed: June 10, 1998
    Date of Patent: November 18, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Richard J. Youle, Veena M. Vasandani, Yon-Neng Wu, Ester Boix, Wojciech Ardelt
  • Mutant form of a cytotoxic ribonucleolytic protein which allows production by recombinant methods
    Patent number: 6649392
    Abstract: The present invention provides recombinant Onc (rOnc) compositions and methods. Recombinant Onc proteins of the invention have an amino terminal methionine and comprise an Onc polypeptide. The amino terminal methionine of the protein allows for recombinant production in a bacterial host cell. Cleaving the amino terminal methionine exposes the amino terminal glutamine of the polypeptide. The Onc polypeptide has an amino terminal glutamine. Cyclization of the amino terminal glutamine of the polypeptide to a pyroglutamyl residue provides rOnc polypeptides and proteins have anti-cancer and anti-viral activity.
    Type: Grant
    Filed: April 4, 1996
    Date of Patent: November 18, 2003
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Richard J. Youle, Veena M. Vasandani, Yon-Neng Wu, Ester Boix, Wojciech Ardelt
  • Family of proteins belonging to the pancreatic ribonuclease a superfamily
    Patent number: 6239257
    Abstract: A protein family includes four proteins that are bioactive against human tumor cell lines. The proteins are derived from eggs of the Rana pipiens frog, and are members of the superfamily of pancreatic ribonucleases.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: May 29, 2001
    Assignee: Alfacell Corporation
    Inventor: Wojciech Ardelt